Adagene (ADAG) vs Innate Pharma S.A. (IPHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adagene (ADAG) has outperformed Innate Pharma S.A. (IPHA) over the past year, gaining 42.2% versus a loss of 26.4%. Over five years, IPHA leads with a -74.8% price change compared with -76.2% for ADAG. Adagene is the larger company by market cap ($186.3 million vs $166.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | IPHA |
|---|---|---|
| Share price | $2.78 | $1.49 |
| Market cap | $186.32M | $166.43M |
| 1-day change | -0.18% | +0.68% |
| YTD return | +47.09% | -15.43% |
| 1-year return | +42.20% | -26.37% |
| 5-year return | -76.24% | -74.79% |
| EPS (TTM) | $-0.37 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.85 | $2.71 |
| 52-week low | $1.30 | $1.17 |
| Distance from 52-week high | -42.78% | -45.02% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +257.12% | +347.65% |
| Average volume | 244.76K | 156.96K |
| Shares outstanding | 67.14M | 111.70M |
| Employees | 128 | 120 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed IPHA by 68.6 percentage points over the past year.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 120 employees
ADAG vs IPHA FAQ
Which is bigger, Adagene or Innate Pharma S.A.?
Adagene (ADAG) is larger, with a market capitalization of $186.32M compared with $166.43M for Innate Pharma S.A. (IPHA).
Which stock has performed better over the past year, ADAG or IPHA?
ADAG returned +42.20% over the past 12 months, compared with -26.37% for IPHA (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and Innate Pharma S.A. in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Adagene and Biotechnology: Biological Products (No Diagnostic Substances) for Innate Pharma S.A..